Compare WH & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WH | PCVX |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.1B |
| IPO Year | N/A | 2020 |
| Metric | WH | PCVX |
|---|---|---|
| Price | $80.40 | $45.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $92.38 | ★ $105.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 02-11-2026 | 02-24-2026 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | ★ 4.33 | N/A |
| Revenue | ★ $1,436,000,000.00 | N/A |
| Revenue This Year | $5.20 | N/A |
| Revenue Next Year | $5.82 | N/A |
| P/E Ratio | $18.13 | ★ N/A |
| Revenue Growth | ★ 3.83 | N/A |
| 52 Week Low | $69.21 | $27.66 |
| 52 Week High | $113.07 | $93.77 |
| Indicator | WH | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 59.37 | 50.27 |
| Support Level | $78.38 | $44.57 |
| Resistance Level | $81.37 | $47.72 |
| Average True Range (ATR) | 2.09 | 1.79 |
| MACD | 0.24 | -0.06 |
| Stochastic Oscillator | 84.70 | 41.16 |
As of June 30, 2025, Wyndham Hotels & Resorts operates 846,700 rooms across more than 20 brands predominantly in the economy and midscale segments. Super 8 is the largest brand, representing around 18% of all rooms, with Days Inn (13%) and Ramada (14%) the next two largest brands, as of the end of 2024. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represents 56% of total rooms, as of the end of 2024.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.